|1.||Zhang, Ying: 19 articles (09/2015 - 01/2002)|
|2.||Nuermberger, Eric L: 16 articles (07/2015 - 02/2004)|
|3.||Grosset, Jacques H: 13 articles (09/2013 - 02/2004)|
|4.||Tyagi, Sandeep: 11 articles (09/2013 - 02/2004)|
|5.||Peloquin, Charles A: 11 articles (08/2013 - 06/2002)|
|6.||McIlleron, Helen: 9 articles (01/2015 - 04/2006)|
|7.||Karakousis, Petros C: 7 articles (08/2013 - 09/2009)|
|8.||Almeida, Deepak: 6 articles (11/2012 - 04/2008)|
|9.||Tasneen, Rokeya: 6 articles (08/2012 - 04/2008)|
|10.||Chaisson, Richard E: 6 articles (07/2012 - 07/2002)|
05/01/2004 - "Pyrazinamide is unique amongst anti-tuberculosis drugs in having no genomic site of action and having greater bactericidal activity as bacillary metabolism slows down; it is remarkably effective in human disease. "
06/01/1991 - "Efficacy of intermittent pyrazinamide in experimental murine tuberculosis."
01/01/1968 - "[A comparative study of the chemotherapeutic efficacy of pyrazinamide and morphozinamide in experimental tuberculosis]."
02/01/2012 - "In a study performed in Cambodia, a higher number of tuberculosis (TB) strains with mutations in the pncA gene associated with pyrazinamide resistance (PZA-R) was found in fluoroquinolone-resistant (FQ-R) multidrug-resistant (MDR) strains (93%), compared with 47% in MDR and 3% in non-MDR strains. "
04/01/2011 - "Clinical studies are warranted to investigate the sterilizing activity and tolerability of higher doses of pyrazinamide in combination tuberculosis regimens."
09/01/2006 - "This study was designed to characterize the population pharmacokinetics of pyrazinamide in South African pulmonary tuberculosis patients, with special reference to interindividual and interoccasional variability (IIV and IOV, respectively). "
01/01/1990 - "[Clinical and laboratory studies in patients with pulmonary tuberculosis treated with pyrazinamide]."
05/01/2015 - "Formulation and Characterization of Pyrazinamide Polymeric Nanoparticles for Pulmonary Tuberculosis: Efficiency for Alveolar Macrophage Targeting."
09/01/2013 - "Treating pyrazinamide mono-resistant pulmonary tuberculosis."
11/01/2012 - "To determine primary and acquired resistance to pyrazinamide in Mycobacterium tuberculosis strains isolated in sputum samples from patients with pulmonary tuberculosis. "
01/01/2013 - "Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection."
03/01/2012 - "bovis infections clinical aspects are varied and treatment is complicated by natural pyrazinamide resistance. "
01/01/2012 - "Pyrazinamide is one of the most important drugs in the treatment of latent Mycobacterium tuberculosis infection. "
02/01/2007 - "All spleens in the pyrazinamide-only treatment group were positive for infection. "
10/01/2001 - "Pyrazinamide (PZA) is one of the most important drugs for the treatment of Mycobacterium tuberculosis infection. "
|4.||Body Weight (Weight, Body)
11/01/2012 - "The objectives of this investigation were to evaluate the impact of body weight on the overall systemic exposure to pyrazinamide (PZA) and to assess whether the use of one fixed dose, without adjustment according to weight, would ensure target exposure and safety requirements across the overall patient population. "
07/01/2010 - "The frequencies of hepatotoxicity were 0.042 (CI, 0.026 to 0.067) for 30 mg/kg of body weight, 0.055 (CI, 0.031 to 0.094) at 40 mg/kg, and 0.098 (CI, 0.047 to 0.193) at 60 mg/kg of pyrazinamide. "
12/01/2009 - "Pyrazinamide serum clearance has been shown to increase with increases in body weight. "
08/01/2009 - "Monte Carlo simulations of 10,000 patients demonstrated that the currently recommended pyrazinamide doses (15 to 30 mg/kg of body weight/day) achieved the AUC(0-24)/MIC of 209.08 in the epithelial lining fluid of only 15.1 to 53.3% of patients. "
06/01/2002 - "Pharmacokinetic parameters of pyrazinamide were independent of human immunodeficiency virus status and patient demographics, except for body weight. "
07/23/2002 - "The current Canadian and US guidelines for the treatment of multidrug-resistant latent tuberculosis infection advocate the use of pyrazinamide and a fluoroquinolone as a first-line treatment option. "
10/15/2005 - "Because earlier randomized trials of rifampin-pyrazinamide lacked adequate statistical power to detect fatal events, the Centers for Disease Control and Prevention recommends that rifampin-pyrazinamide generally should not be used for treatment of latent tuberculosis infection."
08/15/2004 - "Rifampin and pyrazinamide for latent tuberculosis infection: clinical trials and general practice."
05/01/2004 - "A 2-month regimen of rifampin and pyrazinamide (2RZ) became an accepted alternative for treatment of latent tuberculosis (TB) after initial studies in HIV-seropositive patients demonstrated safety and efficacy. "
02/01/2007 - "Safety of the rifampin and pyrazinamide short-course regimen for treating latent tuberculosis infection."
|4.||Streptomycin (Streptomycin Sulfate)
|6.||1- (6- bromo- 2- methoxy- quinolin- 3- yl)- 4- dimethylamino- 2- (3- fluorophenyl)- 1- phenyl- butan- 2- ol (R207910)
|10.||butyl 3-(1H-tetrazol-5-yl)oxanilate (MTB)
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|4.||Directly Observed Therapy